Annovis Bio Appoints Mark Guerin as CFO to Lead Financial Strategy During Critical Late-Stage Trials
Annovis Bio has appointed experienced financial executive Mark Guerin as Chief Financial Officer to guide the company's financial strategy as its lead drug candidate buntanetap advances through late-stage clinical trials for Alzheimer's and Parkinson's disease.
Annovis Bio Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer to lead the company's financial operations during a critical period of late-stage clinical development for its neurodegenerative disease therapies. The appointment comes as Annovis advances buntanetap, its lead drug candidate, through registrational studies for Alzheimer's and Parkinson's disease.
Guerin brings substantial financial leadership experience from his previous role as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: TRAW), where he managed multiple financings and oversaw a merger that formed the new entity. His background includes senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand, providing him with the expertise needed to navigate the complex financial landscape of late-stage biopharmaceutical development.
The timing of this appointment is significant as Annovis works to replicate buntanetap's early success in larger registrational trials. Guerin expressed enthusiasm about supporting the company's mission to deliver solutions for patients suffering from neurodegenerative diseases. His financial leadership will be crucial for managing the substantial resources required for late-stage clinical trials and potential commercialization efforts.
For additional information about Annovis Bio and its development programs, visit https://www.annovisbio.com. Investors can access the latest news and updates relating to ANVS in the company's newsroom at https://ibn.fm/ANVS.
This strategic hire underscores the company's commitment to building a strong leadership team capable of advancing novel therapies for neurodegenerative conditions that affect millions worldwide. The appointment signals Annovis's preparation for the financial complexities of late-stage drug development and potential market entry, positioning the company for sustained growth as it moves closer to regulatory submissions and commercialization decisions.